FIGO Cancer Report 2018: cancer of the vagina
The FIGO review of vaginal cancer: how it is staged, that radiotherapy with brachytherapy is the main treatment, and that adding cisplatin is borrowed from cervical cancer because vaginal cancer is too rare for its own trials.
Overview
FIGO Cancer Report chapter covering the epidemiology, HPV association, diagnosis, FIGO staging and management of primary vaginal cancer, including squamous cell carcinoma, adenocarcinoma and rarer histologies.
It recommends external beam radiotherapy with brachytherapy for most invasive tumours, surgery for selected early lesions, and concurrent cisplatin extrapolated from cervical cancer trials, and it sets out follow-up and the management of recurrence.
The treatment pathway on the vaginal cancer pages, radiotherapy with brachytherapy and cisplatin sensitisation for locally advanced disease, follows this report.
- Recommendations rest on retrospective series and extrapolation from cervical cancer.
- Superseded in detail by later FIGO reports; check the current edition.
Similar pages
not linked directly; found by shared links- TechnologyColposcopy and excisional treatment (LEEP/LLETZ, cone)
Shares Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma), Vaginal squamous cell carcinoma (HPV-associated).
- TermHPV status (HPV-positive / HPV-negative)
Shares Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma), Vaginal squamous cell carcinoma (HPV-associated).
- TermLymphadenectomy (lymph node dissection)
Shares Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma), Vaginal squamous cell carcinoma (HPV-associated).
- CancerVaginal cancer
Shares Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma), Vaginal squamous cell carcinoma (HPV-associated).